CSIMarket Company Name, Ticker, Competitors, else..
 
Anavex Life Sciences Corp   (AVXL)
Other Ticker:  
 
 
Price: $5.7000 $0.39 7.345%
Day's High: $5.73 Week Perf: 13.89 %
Day's Low: $ 5.18 30 Day Perf: -9.67 %
Volume (M): 929 52 Wk High: $ 10.45
Volume (M$): $ 5,294 52 Wk Avg: $5.64
Open: $5.36 52 Wk Low: $3.25



 Market Capitalization (Millions $) 482
 Shares Outstanding (Millions) 85
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -42
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0

Anavex Life Sciences Corp
Anavex Life Sciences Corp (Anavex) is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of central nervous system (CNS) diseases. They are dedicated to addressing unmet medical needs and improving the lives of patients suffering from disorders such as Alzheimer's and Parkinson's disease.

Anavex utilizes a proprietary platform called Sigma-1 Receptor (S1R) to develop small molecule drugs that have the potential to modulate multiple CNS pathways. Their lead investigational product, ANAVEX'2-73, targets neurodegenerative and neurodevelopmental diseases. This drug has shown promising results in preclinical and clinical studies, exhibiting both disease-modifying and symptomatic benefits.

The company also has other drug candidates in its pipeline, including ANAVEX'3-71, which is being developed for the treatment of Rett syndrome and other indications. ANAVEX'3-71 has shown positive results in preclinical studies, demonstrating cognitive improvements and beneficial effects on certain molecular markers.

In addition to their drug development efforts, Anavex actively collaborates with leading academic institutions and research organizations to advance their understanding of CNS diseases and identify potential therapeutic targets. They aim to leverage cutting-edge science and technology to develop novel treatments that can significantly impact patients' lives.

Overall, Anavex Life Sciences Corp is a biopharmaceutical company focused on developing innovative therapies for CNS diseases, with a strong commitment to improving patient outcomes and addressing critical unmet medical needs.


   Company Address: 630 5th Avenue New York 10111 NY
   Company Phone Number: 689-3939   Stock Exchange / Ticker: NASDAQ AVXL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Blarcamesine Breakthrough A Promising Hope in Alzheimer?s Therapy

Published Sun, Jul 28 2024 9:00 PM UTC

In a significant milestone for Alzheimer?s disease (AD) research, Anavex Life Sciences has garnered attention following the presentation of results from their landmark Phase IIb/III trial of Blarcamesine, also referred to as ANAVEX2-73, at the recent Alzheimer's Association International Conference. This progresive study provides a glimmer of hope for those battling this deb...
Anavex Life Sciences Corp

AVXL's Lackluster Financial Performance Raises Concerns for Investors



Anavex Life Sciences Corp, a biopharmaceutical company, recently reported its financial results for the period ending March 31, 2024. The company experienced a narrowed net loss per share compared to the previous year, while the revenue remained unchanged. In addition, various law firms have initiated legal consultations and filed class-action lawsuits against Anavex. This article aims to analyze the significance of these financial results and explore the potential implications for the company's future.
1. Reduced Loss per Share:
Anavex Life Sciences Corp reported a narrower loss per share of $-0.13 in the financial period ending March 31, 2024, compared to $-0.17 in the previous year. This indicates that the company has made progress in reducing its financial losses. However, it is important to note that the loss per share remains negative, suggesting that the company is yet to achieve profitability.
Announcement

Potential Legal Actions Loom as Law Firms Reach Out To Anavex Life Sciences Corporation Investors

Published Thu, May 9 2024 4:28 PM UTC

According to recent notices, shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL) have been urged by The Gross Law Firm for potential legal consultations concerning their rights by May 13, 2024. The exact nature and subject matter of these potential conversations have yet to be openly specified, but the call by the law firm does come in the wake of an earlier anno...
Announcement

Anavex Life Sciences Corp. Faces Class Action Lawsuit: Key Facts and Implications

Published Tue, Apr 16 2024 4:14 PM UTC

Anavex Life Sciences Corp., a biopharmaceutical company listed on NASDAQ under the ticker AVXL, is currently facing a class action lawsuit. This article aims to provide an overview of the situation, including the key facts surrounding the lawsuit, potential implications for the company, and ways for affected investors to seek legal recourse.Background:On April 16, 2024, Pom...
Announcement

Class-Action Lawsuit Targets Anavex Life Sciences Corporation's Alleged Misrepresentation and Deceptive Practices

Published Thu, Mar 14 2024 4:04 PM UTC

Gainey McKenna & Egleston, a New York-based law firm, has recently revealed that a class-action lawsuit has been filed against biopharmaceutical company Anavex Life Sciences Corporation (Anavex) in the United States District Court for the Southern District of New York. This lawsuit represents all individuals and entities who purchased or obtained securities of Anavex between...






Anavex Life Sciences's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com